Julia M Tilton

Julia Tilton serves as a key procurement lead within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through advanced scientific infrastructure and diagnostic innovation. She manages a portfolio of high-complexity acquisitions focused on laboratory testing services and translational research support, ensuring alignment with NCI’s strategic priorities in genomic analysis, precision medicine, and molecular diagnostics. Her work directly enables the deployment of cutting-edge technologies by securing contracts with industry leaders capable of delivering scalable, compliant, and high-throughput testing capabilities. Tilton’s acquisitions are primarily governed by scientific rigor and regulatory compliance, with a strong emphasis on quality assurance and data integrity standards. Her primary contractor relationship is with Roche Diagnostics Corporation, a global leader in in vitro diagnostics and molecular testing platforms. She consistently engages with this vendor to procure advanced laboratory systems, assay kits, and bioinformatics services critical to large-scale cancer biomarker studies. Her contracting patterns reflect a preference for established, high-capacity providers with proven expertise in CLIA-certified environments and FDA-cleared technologies, indicating a focus on reliability and scalability over vendor diversity. Tilton’s procurement portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects the specialized nature of the services required, which demand technical capabilities beyond the typical capacity of small or socioeconomic small businesses in this domain. While small business participation is not structurally prioritized, her acquisitions remain fully compliant with federal procurement regulations and competitive bidding requirements. Her primary NAICS classification is 541380 (Testing Laboratories and Services), underscoring her deep specialization in procuring clinical and research laboratory services, including next-generation sequencing, liquid biopsy analysis, and multiplexed molecular assays. She routinely acquires end-to-end diagnostic solutions that integrate instrumentation, reagents, data analysis software, and quality control protocols, supporting NCI’s mission to translate laboratory discoveries into clinical applications.